Intracameral bevacizumab for rubeotic glaucoma secondary to retinal vein occlusion.
Two patients with ischaemic central retinal vein occlusion were treated with intracameral bevacizumab in order to affect the outcome of their disease. In addition, both patients underwent episodes of cycloablative and pan-retinal laser treatment. The patients were followed for more than 6 months and achieved some stability with a combination of these modalities.